--- canonical_name: Larazotide alternate_names: Larazotide Acetate, AT-1001, AT1001, INN-202 canonical_topic: Larazotide for Health & Longevity short_topic_lc: larazotide creation_date: 2026-0912-0234 creator_ai_fullname: Opus 5 ep_keywords: Zonulin Antagonists, Tight Junction Regulators --- # Larazotide for Health & Longevity

Evidence Review created on 09/12/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** Larazotide Acetate, AT-1001, AT1001, INN-202 ## Motivation Larazotide is a small protein fragment, administered orally, that was designed to tighten the seals between the cells lining the small intestine. Those seals act as a gate: when they loosen, fragments of food and microbes that would normally stay inside the gut can cross into the tissue beneath and provoke an immune response. Larazotide works only inside the gut and is not absorbed into the bloodstream. The idea grew out of work on a cholera toxin that pries those seals open, and on a human protein that appears to do the same thing when wheat protein reaches the gut lining. Larazotide has been tested mainly in adults with celiac disease who still have digestive symptoms despite avoiding gluten, and more recently in children and young adults who remained ill after a coronavirus infection. Interest beyond those settings rests on the idea that a loosened gut barrier feeds wider inflammation relevant to long-term health. This review examines what those human trials actually measured, how large and how consistent the effects were, what the safety record shows, who funded the work, and where the evidence runs out. It also sets out what is known about dosing, sourcing, and monitoring. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section collects high-level overviews of larazotide and of zonulin (the human protein that loosens the seals between gut-lining cells), the target it was built around, drawn from expert commentary and qualifying academic articles. * [Pioneering Researcher Alessio Fasano M.D. on Gluten, Autoimmunity & Leaky Gut](https://chriskresser.com/pioneering-researcher-alessio-fasano-m-d-on-gluten-autoimmunity-leaky-gut/) - Chris Kresser Fasano, who discovered zonulin, is asked directly about larazotide's clinical progress and safety record, giving the originator's own account of the drug's rationale and its place alongside a gluten-free diet. * [Larazotide acetate: a pharmacological peptide approach to tight junction regulation](https://pubmed.ncbi.nlm.nih.gov/33881350/) - Slifer et al., 2021 The most current narrative review of larazotide's mechanism, extending it past celiac disease to animal models of arthritis and of intestinal injury caused by interrupted blood flow. * [The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate](https://pubmed.ncbi.nlm.nih.gov/26770266/) - Khaleghi et al., 2016 A narrative review that walks through the whole phase 1 and phase 2 trial program dose by dose, and is the clearest published account of why higher doses worked less well. * [Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial](https://pubmed.ncbi.nlm.nih.gov/25683116/) - Leffler et al., 2015 The largest completed and published larazotide trial, and the source of nearly every efficacy figure quoted for the drug; reading the primary report shows how mixed the result actually was. * [Celiac Disease and Non-Celiac Gluten Sensitivity](https://www.lifeextension.com/protocols/gastrointestinal/celiac-disease-and-non-celiac-gluten-sensitivity) - Robert Iafelice A longevity publication's consumer-facing account of celiac disease that sets larazotide's zonulin-blocking rationale and early trial results alongside the dietary and nutrient strategies it reviews at length. Content from the other priority platforms could not be included: searches of foundmyfitness.com, peterattiamd.com, hubermanlab.com and lifespan.io returned no material that discusses larazotide or zonulin-targeted barrier therapy by name, so no item from those sources would satisfy the relevance bar. ## Grokipedia * [Larazotide](https://grokipedia.com/page/larazotide) Sets out the peptide's structure, receptor pharmacology and full development history in one place, including the 2022 phase 3 discontinuation and the preclinical work outside celiac disease. ## Examine No Examine article on larazotide exists. Examine.com covers dietary supplements and nutrition compounds; larazotide is an investigational prescription-track drug that has never been marketed as a supplement, so it falls outside the site's scope. ## ConsumerLab No ConsumerLab article on larazotide exists. ConsumerLab tests marketed supplements, foods and consumer health products; larazotide is an investigational prescription-track drug and is not covered by that testing program. ## Systematic Reviews This section lists the systematic reviews and meta-analyses that pool the human trial data on larazotide. * [Larazotide acetate for treatment of celiac disease: A systematic review and meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/34339872/) - Hoilat et al., 2022 Pools all four randomized controlled trials (626 patients) on both efficacy and adverse events, and is the single most complete quantitative account of the drug. * [Celiac disease: Hope for new treatments beyond a gluten-free diet](https://pubmed.ncbi.nlm.nih.gov/38648685/) - D'heedene et al., 2024 Systematic review of every celiac drug that reached a phase 1–3 trial, placing larazotide's barrier-modulating approach against gluten-degrading enzymes and transglutaminase blockers. Larazotide's central trade-off is symptom relief set against the possibility that a barrier drug relaxes gluten vigilance without protecting the intestinal lining. The Hoilat meta-analysis covers the claimed effect and pools adverse events, but no systematic review or meta-analysis addresses the forgone benefit of strict dietary adherence under drug cover; that side of the trade-off is unrepresented in the systematic review literature. ## Mechanism of Action In celiac disease, gluten fragments reaching the intestinal lining trigger release of zonulin, a human protein that loosens the tight junctions (the protein seals that lock neighbouring gut-lining cells together). Loosened junctions let gluten peptides pass between cells rather than through them, where tissue transglutaminase (an enzyme that chemically alters those fragments) converts them into forms that HLA-DQ2 and HLA-DQ8 (immune-presenting molecules) display to T cells, driving the inflammation that flattens the intestinal surface. Larazotide is an eight-amino-acid peptide whose sequence derives from the zonula occludens toxin of *Vibrio cholerae*. Administered orally, it stays in the gut lumen and blocks the zonulin signal, promoting reassembly of tight junction proteins and the actin filaments anchoring them. It also inhibits myosin light chain kinase (an enzyme that generates tension in those filaments), which relaxes the pull on the junction and lets it close ([Slifer et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33881350/)). Two mechanistic readings compete. The originating account treats larazotide as a zonulin-receptor antagonist. A dissenting account holds that the identity of circulating zonulin and its receptor remains unsettled, and that larazotide's effect is a direct action on myosin light chain kinase and actin, independent of zonulin. Pharmacologically it is unusual: plasma concentrations stay below 0.5 ng/mL after oral doses up to 36 mg, so there is no measurable systemic exposure, no meaningful elimination half-life, and no liver enzyme metabolism. It is degraded by gut peptidases and is formulated as delayed-release beads targeting the duodenum and jejunum. ## Historical Context & Evolution Larazotide originates in Alessio Fasano's laboratory work on *Vibrio cholerae*. Researchers there characterized zonula occludens toxin, the cholera-associated protein that opens intestinal tight junctions, and in 2000 reported a human counterpart they named zonulin. Larazotide was engineered from the toxin's active fragment to occupy the same site without opening the junction. Its original intended use was narrow and explicitly adjunctive: an oral medication for celiac disease, taken alongside — never instead of — a gluten-free diet, to blunt the effect of inadvertent gluten exposure. Alba Therapeutics took it into phase 1 in 2005. The first-in-human celiac study found a 70% rise in intestinal permeability after acute gluten exposure in the placebo arm and none in the treated arm, with fewer gastrointestinal symptoms ([Paterson et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17697209/)). Two larger gluten-challenge trials then failed to reproduce the permeability finding while still showing symptom benefit ([Leffler et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22825365/); [Kelly et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23163616/)). Interest broadened to health optimization because the same barrier biology was invoked for conditions far outside celiac disease, and larazotide became the reference compound for pharmacological "leaky gut" repair. The program passed from Alba to Innovate Biopharmaceuticals and then to 9 Meters Biopharma, which halted its phase 3 trial for futility in 2022. Scientific opinion has not settled: the zonulin construct remains contested — commercial zonulin assays have been shown to detect other proteins — while independent laboratories continue to report barrier effects for the peptide itself. ## Expected Benefits ### High 🟩 🟩 🟩 #### Blunted Gluten-Triggered Symptom Flares During Gluten Exposure In two randomized gluten-challenge trials in adults with celiac disease — 86 patients at 2.4 g gluten daily ([Leffler et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22825365/)) and 184 at 2.7 g daily ([Kelly et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23163616/)) — larazotide reduced the gluten-induced worsening of Gastrointestinal Symptom Rating Scale scores, a validated symptom instrument. The meta-analysis pooling all four trials confirms a significant advantage over placebo in challenged patients ([Hoilat et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34339872/)). Both trials were sponsor-run. The effect does not rise with dose: it appears at low doses and vanishes at high ones. **Magnitude:** Pooling the gluten-challenge trials, larazotide lowered the Gastrointestinal Symptom Rating Scale score by a mean difference of 0.20 points against placebo (95% confidence interval 0.01 to 0.40 — the range within which the true value most likely lies) and the celiac-specific version of the same scale by 0.26 points (95% confidence interval 0.03 to 0.49). The effect holds at 0.25–1 mg three times daily under a 2.4–2.7 g daily gluten challenge and is absent at 4–8 mg (P = 0.002 for 1 mg in the 184-patient trial, where P is the probability that a difference this large arose by chance). ### Medium 🟩 🟩 #### Suppressed Antibody Response to Gluten Exposure In the 184-patient gluten-challenge trial, larazotide markedly limited the rise in antibodies to tissue transglutaminase (the enzyme targeted by the celiac immune response, and the standard blood marker of disease activity) ([Kelly et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23163616/)). The marker is validated against intestinal damage in people, but came from one sponsor-run trial; the shorter companion challenge trial measured the same antibody but produced no significant rise even in its placebo arm, so replication is absent. Whether the blunted antibody rise translates into a preserved intestinal lining was never tested by biopsy. **Magnitude:** Mean antibody level relative to each patient's own baseline was 19.0-fold in the placebo arm versus 5.78-fold at 1 mg, 3.88-fold at 4 mg and 7.72-fold at 8 mg three times daily over six weeks. #### Faster Recovery in Post-COVID Multisystem Inflammatory Syndrome in Children In a phase 2a randomized, double-blind, placebo-controlled trial of 12 hospitalized children (median age 5.7 years), larazotide added to standard immune-suppressing care produced faster resolution of gastrointestinal symptoms, faster clearance of viral spike protein from blood, and a faster return to usual activities ([Yonker et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40737433/)). These are clinical endpoints from a single small academic trial, consistent with an earlier four-patient case series ([Yonker et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35211683/)). The trial was investigator-initiated, not company-sponsored. **Magnitude:** The direction is faster symptom resolution and antigen clearance versus placebo, holding in hospitalized children treated four times daily for 21 days alongside steroids or antibody infusions; with 12 participants the trial reports no effect-size figure, and the preceding case series reported only significance values (P = 0.03 for symptom resolution, P = 0.04 for antigen clearance). ### Low 🟩 #### Relief of Persistent Digestive Symptoms on a Gluten-Free Diet ⚠️ Conflicted The 342-patient phase 2b trial met its primary endpoint at 0.5 mg three times daily ([Leffler et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25683116/)). The 307-patient phase 3 trial in the same population switched to a binary responder endpoint and stopped for futility ([NCT03569007](https://clinicaltrials.gov/study/NCT03569007)). Net reading: the later trial did not confirm the earlier one. **Magnitude:** In the positive phase 2b trial, 26% fewer symptomatic days and 31% more improved-symptom days versus placebo at 0.5 mg three times daily; the phase 3 trial produced no effect large enough to continue enrollment. ### Speculative 🟨 #### Prevention of the Gluten-Induced Rise in Intestinal Permeability ⚠️ Conflicted The first-in-human trial found no permeability rise versus 70% on placebo ([Paterson et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17697209/)), but two larger trials found no difference on the same unvalidated urinary marker ([Kelly et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23163616/)). Net reading: unreplicated. #### Prevention of Inflammatory Arthritis Onset In mice, restoring barrier integrity with larazotide before disease onset reduced arthritis development ([Tajik et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32332732/)). Basis is animal work only; no human study has tested this. #### Prevention of Autoimmune Diabetes Onset In diabetes-prone rats, blocking the zonulin receptor with larazotide cut cumulative type 1 diabetes incidence by 70% ([Watts et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15710870/)). Basis is animal work only; it has never been tested in people. #### Protection Against Fatty Liver Disease A mouse model reported that larazotide limited development of non-alcoholic fatty liver disease ([Huang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/40562584/)). Basis is a single animal experiment with no human counterpart. #### Mucosal Recovery After Intestinal Blood-Flow Injury In pigs, larazotide accelerated repair of tight junctions in jejunum injured by interrupted blood flow ([Slifer et al., 2021](https://pubmed.ncbi.nlm.nih.gov/33886649/)). Basis is large-animal work only; no human data exist. ## Benefit-Modifying Factors * **Immune-presenting gene type:** Larazotide's celiac benefit depends on the gluten–zonulin pathway, which requires the HLA-DQ2 or HLA-DQ8 immune-presenting gene variants. People without them do not have celiac disease and have no evidence base for benefit. * **Haptoglobin gene variant:** Zonulin is a form of the blood protein haptoglobin, made only by carriers of the HP2 variant (one of two common versions of the haptoglobin gene). People carrying only HP1 may have little of the drug's target. * **Baseline symptom burden and gluten exposure:** Benefit was measurable only in patients with active symptoms or deliberate gluten challenge. Detectable gluten fragments in stool identify the ongoing exposure the drug is meant to buffer. * **Sex:** Celiac trial populations were roughly three-quarters female, mirroring disease prevalence. No trial reported a sex-stratified efficacy analysis, so any sex difference in response is unmeasured rather than absent. * **Coexisting conditions:** Refractory celiac disease (celiac disease that does not respond to a gluten-free diet) and other active gut disease were excluded from every trial. Overlapping irritable bowel syndrome or bacterial overgrowth can dominate symptoms and mask any barrier effect. * **Age:** Celiac evidence comes entirely from adults aged 18 and over, with older adults sparsely represented. Paediatric data exist only from the small post-viral trials, where dosing was weight-based. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 #### Headache Headache is the most frequently reported adverse event in larazotide trials, recorded across the gluten-challenge and gluten-free-diet studies and in phase 1 work in healthy volunteers. In the 86-patient challenge trial it was the commonest event with no difference between treatment groups ([Leffler et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22825365/)), and the pooled analysis of all four randomized trials found adverse events other than gluten-related diarrhea comparable to placebo ([Hoilat et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34339872/)). It is mild and reversible on stopping. All these trials were run by the drug's commercial owners. **Magnitude:** Reported by 17 of 86 patients (roughly 20%) in the challenge trial, distributed evenly across larazotide and placebo arms, so the attributable excess over placebo is close to zero. #### Loss of Symptom Benefit at Higher Doses Larazotide's dose-response is inverted: the symptom benefit appears at the lowest doses tested and disappears as the dose rises. The 342-patient trial found 1 mg and 2 mg three times daily no different from placebo on any endpoint while 0.5 mg met the primary endpoint ([Leffler et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25683116/)), and the same pattern appeared in the challenge trials at 4 mg and 8 mg ([Kelly et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23163616/)). The proposed explanation is that excess peptide self-associates and loses activity. Dose escalation therefore forfeits whatever effect exists. **Magnitude:** The direction is a complete loss of measurable symptom benefit as the dose rises above 0.5 mg three times daily, holding in the 342-patient trial where the 1 mg and 2 mg arms differed from placebo on no endpoint at all and in the challenge trials at 4 mg and 8 mg; the literature reports no outcome figure for the size of the loss. #### Gastrointestinal Adverse Events Abdominal pain, flatulence, nausea, abdominal distension and altered stool were reported throughout the trial program, unsurprisingly given the target population. Pooling all four randomized trials found these events comparable between larazotide and placebo, and gluten-related diarrhea was actually less frequent on larazotide during gluten challenge ([Hoilat et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34339872/)). They are difficult to separate from the underlying disease. All four pooled trials were sponsor-conducted, which is the usual setting for under-ascertainment of mild events. **Magnitude:** Across a pooled analysis of 626 patients (465 on larazotide, 161 on placebo), gluten-related diarrhea was less frequent on larazotide at a risk ratio of 0.42 (95% confidence interval 0.25 to 0.72; a risk ratio below 1 means fewer events on the drug than on placebo), gluten-related flatulence showed no difference at 0.70 (95% confidence interval 0.36 to 1.39), and the rate of having any adverse event at all was 0.99 (95% confidence interval 0.86 to 1.13). ### Medium 🟥 🟥 #### Urinary Tract Infection Urinary tract infection was the second most common adverse event in the 86-patient gluten-challenge trial, occurring in 5.8% of participants with no dose relationship and no serious cases ([Leffler et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22825365/)). It has not been flagged as a signal in the larger trials or in the pooled safety analysis, and no mechanism links a non-absorbed intraluminal peptide to urinary infection. The trial investigators judged none of the cases to be drug-related. **Magnitude:** 5 of 86 patients (5.8%), all of them in larazotide plus gluten-challenge arms and none on placebo; not identified as an excess over placebo in any larger trial. ### Low 🟥 #### Unknown Safety Beyond Six Months No human has been followed on larazotide beyond 24 weeks in any registered trial — the celiac studies dosed for 12 weeks or less — and roughly 1,000 people in total have ever been exposed ([Hoilat et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34339872/)). Long-term consequences of sustained tight junction modulation are untested. **Magnitude:** Not quantified in available studies. No trial has run beyond 24 weeks, so no exposure-duration data exist from which a long-term rate could be estimated. ### Speculative 🟨 #### Relaxed Gluten Vigilance Under Unproven Mucosal Cover No trial measured intestinal architecture, so barrier protection against gluten damage is unproven. Treating the drug as cover for dietary lapses has never been studied in humans. #### Product Quality Failure From Unregulated Suppliers Larazotide sold as a research peptide is made outside pharmaceutical oversight. No published analysis has tested identity, purity or delivery of these products, so contamination and mislabeling risks are unmeasured. ## Risk-Modifying Factors * **Absence of pharmacogenetic modifiers:** No genetic variant is known to modify larazotide's safety. Because the peptide is not absorbed and not broken down by liver enzymes, the gene variants that govern drug metabolism are irrelevant to how it is handled. * **Baseline liver and kidney markers:** Trials excluded liver enzymes at or above three times the upper limit of normal, bilirubin at twice that limit, and kidney filtration at or below 50 mL/min/1.73 m². Safety in those states is untested. * **Sex:** No sex difference in adverse event rates has been reported. Because celiac cohorts were roughly three-quarters female, the male safety dataset is thin and any male-specific signal would likely have been missed. * **Coexisting gut disease:** Chronic active gastrointestinal disease other than celiac disease was excluded from every trial. Safety in inflammatory bowel disease, refractory celiac disease or short bowel syndrome is untested. * **Age:** Safety data cover adults 18 and over from celiac trials and children from age three in the post-viral trials. No data exist for adults over 65, during pregnancy, or while breastfeeding. ## Key Interactions & Contraindications * **Drugs absorbed between gut cells:** No formal interaction study exists. Tightening tight junctions could in theory reduce absorption of hydrophilic drugs taking that route (atenolol, metformin, aminoglycosides such as gentamicin — injectable antibiotics). Severity: caution. Mitigation: separate dosing by two hours and monitor drug effect. * **Non-steroidal anti-inflammatory drugs:** Ibuprofen, naproxen and aspirin increase intestinal permeability, directly opposing larazotide's action and plausibly negating it. Severity: caution. Mitigation: minimize use, or separate from dosing; no dose adjustment is established. * **Oral proteolytic enzyme supplements:** Bromelain, papain and serrapeptase (enzymes that break down proteins) degrade peptides in the gut and may destroy larazotide before it reaches its site of action. Severity: caution. Mitigation: separate by at least two hours. * **Barrier-supporting supplements:** Zinc carnosine, L-glutamine, colostrum and quercetin are promoted for the same tight junction endpoint and would be expected to act additively. Severity: monitor only; no harm signal exists, and no combination has been tested. * **Alcohol:** Ethanol increases intestinal permeability and opposes the intended effect, in the same direction as anti-inflammatory drugs. Severity: caution. Mitigation: reduced intake during any trial of the drug. * **Gluten-free diet:** Not an interaction to avoid but the obligatory co-intervention; every trial required continued strict adherence. Severity: caution — abandoning the diet forfeits the only proven protection against intestinal damage. Mitigation: maintain full avoidance. **Populations who should avoid Larazotide:** * Pregnant or breastfeeding women — excluded from every trial, no reproductive safety data * Children under 7 years outside a supervised trial — youngest published exposure was age 3 under an emergency authorization * People with liver enzymes ≥3× the upper limit of normal, or total bilirubin ≥2× the upper limit of normal * People with kidney filtration ≤50 mL/min/1.73 m² * People with refractory celiac disease (Type I or Type II) or severe celiac complications such as ulcerative jejunitis (ulcers forming in the small intestine) * People with chronic active gastrointestinal disease other than celiac disease * People with known hypersensitivity to larazotide or its formulation components ## Risk Mitigation Strategies * **Fixed low dose with no escalation:** Holding at 0.5 mg three times daily, the only dose that met an endpoint, avoids the documented loss of benefit at 1 mg and above rather than assuming more is better. * **Unchanged strict gluten-free diet:** Maintaining full dietary avoidance throughout addresses the unproven mucosal-protection risk, since no trial measured intestinal architecture and every trial required continued adherence. * **Defined trial window with a stop rule:** A 12-week limit matching the trial durations, discontinued if symptom scores have not fallen by roughly 30%, limits exposure given the absence of safety data beyond 24 weeks. * **Serology and nutrient labs at baseline and 12 weeks:** Repeating tissue transglutaminase antibodies, ferritin and vitamin D detects silent relapse of intestinal damage that symptom improvement alone would mask. * **Liver enzymes and kidney filtration before starting:** A metabolic panel confirms the thresholds that excluded participants from trials are not breached, addressing the untested safety in hepatic and renal impairment. * **Certificate of analysis for any sourced material:** Requiring batch identity and purity data by mass spectrometry and chromatography addresses the unmeasured contamination risk from unregulated peptide suppliers. * **Two-hour separation from protein-digesting enzymes and certain drugs:** Spacing doses addresses both degradation of the peptide and the theoretical reduction in absorption of drugs such as atenolol or metformin. ## Therapeutic Protocol * **Standard dose:** 0.5 mg three times daily is the regimen used by the trial program's investigators at Beth Israel Deaconess, Columbia and Mayo Clinic, and the only dose that met a primary endpoint. * **Timing relative to meals:** Capsules are administered roughly 15 minutes before each main meal, so the peptide is present in the lumen when gluten arrives rather than after junctions have opened. * **Formulation:** Delayed-release enteric beads in a capsule, designed to release in the mid duodenum and jejunum. Immediate-release powder would be degraded before reaching the target segment. * **Competing approaches:** Conventional gastroenterology uses strict dietary avoidance alone with no drug. Investigational practice adds an adjunctive barrier agent. Functional medicine stacks nutrient barrier support. None is established as the default. * **Half-life:** There is no measurable systemic half-life; plasma levels stay below 0.5 ng/mL even at 36 mg. Duration of action is set by gut transit, which is why dosing is meal-linked. * **Split versus single dose:** Splitting is obligatory, not optional. Because action is local and transit-limited, a single daily dose would leave two of three meals uncovered; every trial used three or four daily doses. * **Genetic factors in dose choice:** No pharmacogenetic dosing exists. HLA-DQ2 or HLA-DQ8 status and the HP2 haptoglobin variant determine whether the target pathway is present at all, not how much drug is needed. * **Sex differences:** No sex-based difference in response, dosing or efficacy has been demonstrated. Trials were female-predominant and none reported a sex-stratified dose analysis. * **Age considerations:** Adult protocols are fixed-dose. Paediatric trials used weight-based dosing of 250 µg below 25 kg and 500 µg at or above 25 kg, four times daily. No protocol exists for adults over 65. * **Baseline markers guiding response:** A documented symptom score, tissue transglutaminase antibody level and stool gluten-fragment test establish whether active exposure and active disease are present to respond. * **Pre-existing conditions:** Refractory celiac disease, other active gut disease and significant liver or kidney impairment placed patients outside every trial protocol and outside the dosing evidence. ## Discontinuation & Cycling * **Intended duration:** Trials ran 2 to 24 weeks and the drug was conceived as continuous adjunctive therapy for a lifelong condition. No maintenance data beyond 24 weeks exist to support indefinite use. * **Withdrawal effects:** None reported. The 342-patient trial included a four-week placebo run-out phase after 12 weeks of treatment and recorded no rebound in symptoms on stopping ([Leffler et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25683116/)). * **Tapering:** No taper is described in any protocol. Because the peptide is not absorbed and has no measurable systemic exposure, abrupt discontinuation is how every trial ended dosing. * **Cycling:** No cycling regimen has been studied and no loss of effect with repeated dosing has been reported. Dosing is inherently intermittent, tied to meals rather than to continuous plasma coverage. * **Stopping for non-response:** Trial endpoints were assessed at 6 to 12 weeks, so a defined review point at 12 weeks matches the interval over which benefit either appeared or did not. ## Sourcing and Quality * **No approved product exists:** Larazotide is not approved by any regulator, so no pharmaceutical-grade finished product is legitimately available. Every consumer source is outside the approved supply chain. * **Research-peptide vendors:** Material sold online as research peptide is manufactured without regulatory oversight. Labeled identity, purity, bacterial contamination and actual peptide content are unverified, and no published analysis has tested these products. * **Compounding pharmacies:** Larazotide is not a component of an approved drug and does not appear on the bulk substances list permitting compounding, so a legitimate compounded preparation is not obtainable in the United States. * **What to look for:** A batch certificate of analysis showing mass-spectrometry identity confirmation and chromatographic purity at or above 98%, with peptide content stated net of counter-ion and water, is the minimum documentation. * **Formulation matters more than purity:** The trial product was delayed-release beads releasing in the mid duodenum and jejunum. Loose powder or a plain capsule does not reproduce the delivery the efficacy data rest on. ## Practical Considerations * **Time to effect:** Symptom differences emerged within one to two weeks of gluten challenge in the shortest trials, while the endpoint-defining trials measured effects at 6 and 12 weeks. Barrier effects are not cumulative over months. * **Common pitfalls:** Escalating the dose, which abolishes the effect; treating the drug as licence to eat gluten, which no trial supports; and using immediate-release material that never reaches the target segment. * **Regulatory status:** Investigational only. The phase 3 celiac program was halted in 2022 and no marketing application has been filed anywhere. Material sold for research use is not authorised for human consumption. * **Cost and accessibility:** The peptide itself is inexpensive to synthesize, but legitimate access is effectively zero outside a clinical trial. Difficulty of access, not price, is the binding constraint. * **Payer incentives shape the comparison:** The competing intervention, a gluten-free diet, costs institutional payers nothing, giving insurers and national health systems a structural reason to favor it over any drug — a potential source of bias in guideline formation and research funding. ## Interaction with Foundational Habits * **Sleep:** Direct interaction is absent, since there is no systemic exposure to disturb sleep architecture. An indirect improvement is plausible: the 342-patient trial recorded reductions in tiredness and headache alongside digestive symptoms ([Leffler et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25683116/)), and no trial reported insomnia. Dosing timing is dictated by meals, not by bedtime. * **Nutrition:** Directly interacting and inseparable from the intervention. Doses are administered about 15 minutes before meals, and a strict gluten-free diet is the obligatory background. Alcohol and non-steroidal anti-inflammatory drugs raise intestinal permeability and work against the drug; proteolytic enzyme supplements may digest it. * **Exercise:** Indirect and untested. Prolonged strenuous endurance exercise raises intestinal permeability and circulating zonulin as blood is diverted away from the gut, acting on the same junctions larazotide targets, making a complementary effect mechanistically plausible. No trial has examined larazotide around exercise, and no timing recommendation has an evidence base. * **Stress management:** Indirect and potentiating in principle. Psychological stress increases intestinal permeability through stress-hormone and immune-cell signaling in the gut lining, opening the junctions larazotide closes. Reducing that input addresses an upstream driver the drug can only counter downstream. No trial has tested the combination. ## Monitoring Protocol & Defining Success Baseline testing establishes both that active celiac disease is present and that the thresholds excluding trial participants are not breached. It covers celiac antibody testing, nutrient status reflecting absorption, and liver and kidney function, together with a documented symptom score against which change can be judged. Ongoing monitoring follows the trial cadence: symptom scoring weekly for the first four weeks, then a full repeat of antibody testing, nutrient markers and metabolic panel at 12 weeks, and every 6 months thereafter if dosing continues. The 12-week point is decisive, because it is where the trials either demonstrated benefit or did not. Success is defined by symptom improvement that does not come at the cost of rising antibody levels, which would signal continuing mucosal damage beneath an improved symptom picture. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Tissue transglutaminase IgA (tTG-IgA) | Negative, below 4 U/mL | Tracks the ongoing immune response to gluten | tTG-IgA is immunoglobulin A (IgA, the main antibody class of the gut lining) directed at tissue transglutaminase; it is the standard celiac antibody. Requires normal total IgA to interpret; conventional labs call anything under 15 U/mL negative | | Deamidated gliadin peptide IgA and IgG (DGP) | Negative | Catches disease activity when tTG-IgA is uninformative | DGP is deamidated gliadin peptide, a second celiac antibody target; IgG is immunoglobulin G, the main antibody class circulating in blood. Useful in IgA deficiency; conventional cut-offs are less sensitive to low-grade exposure | | Total IgA | 90–400 mg/dL | Confirms the antibody tests above are valid | Selective IgA deficiency, in which this antibody class is largely absent, is roughly 10 times more common in celiac disease than in the general population | | Fecal gluten immunogenic peptides (GIP) | Undetectable | Shows whether gluten is still reaching the gut | GIP are gluten immunogenic peptides, undigested gluten fragments excreted in stool. Reflects the previous 1–3 days; conventional practice relies on dietary recall instead | | Ferritin | 50–150 ng/mL men, 40–120 ng/mL women | Earliest marker of impaired absorption | Ferritin is the iron storage protein. Conventional range starts at 15 ng/mL; it rises with inflammation, so interpret alongside an inflammation marker | | 25-hydroxyvitamin D | 40–60 ng/mL | Fat-soluble nutrient absorption and bone status | Conventional sufficiency starts at 30 ng/mL; no fasting required, and season of sampling matters | | Vitamin B12 | 500–900 pg/mL | Absorption in the far end of the small intestine | Conventional range starts near 200 pg/mL; methylmalonic acid confirms borderline values | | Alanine aminotransferase (ALT) | 10–26 U/L | Safety threshold and celiac-related liver involvement | ALT is alanine aminotransferase, a liver enzyme released when liver cells are stressed. Conventional laboratories call anything up to 40–55 U/L normal; trials excluded values at or above 3× that upper limit; fasting sample preferred | | Estimated glomerular filtration rate (eGFR) | Above 90 mL/min/1.73 m² | Safety threshold used in the trials | eGFR is the estimated glomerular filtration rate, a calculated measure of kidney filtering capacity. Conventional practice treats anything above 60 mL/min/1.73 m² as normal; trials excluded values at or below 50 mL/min/1.73 m²; avoid heavy protein meals and creatine the day before | | High-sensitivity C-reactive protein (hs-CRP) | Below 1.0 mg/L | Background inflammatory burden | hs-CRP is high-sensitivity C-reactive protein, a general marker of body-wide inflammation. Conventional risk cut-off is 3.0 mg/L; invalid within two weeks of infection or injury | | Serum zonulin | No established target; track change from the individual's own baseline | Proposed proxy for barrier leakiness | Commercial assays have been shown to detect other proteins, so results are exploratory only and carry no established decision threshold | Qualitative markers worth tracking alongside the laboratory panel: * Frequency and severity of abdominal pain, bloating and loose stools, scored the same way each week * Number of symptom-free days per week, the endpoint that moved in the phase 2b trial ([Leffler et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25683116/)) * Tiredness and headache, both of which improved alongside digestive symptoms in that trial * Confidence eating outside the home, which is the practical reason the drug was developed * Cognitive clarity and mood, commonly reported in celiac disease and unmeasured in the trials ## Emerging Research * **Empty recruitment pipeline:** No larazotide trial is currently recruiting; all ten registered larazotide studies are completed or terminated. The research pipeline has passed from industry to academic investigators, and no company is pursuing a marketing application. * **Long COVID trial completed, results pending:** [NCT05747534](https://clinicaltrials.gov/study/NCT05747534), a phase 2a randomized, double-blind, placebo-controlled trial at Massachusetts General Hospital, enrolled 107 participants aged 7 to 50 with persistent post-viral symptoms and viral antigen in blood, dosing 250–500 µg four times daily for 21 days. It completed in June 2026. * **Post-viral inflammatory syndrome in children:** [NCT05022303](https://clinicaltrials.gov/study/NCT05022303) was terminated after 12 of a larger planned enrollment but was published in full ([Yonker et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40737433/)). Whether the antigen-clearance signal survives a properly powered trial is the open question. * **The halted phase 3 celiac trial:** [NCT03569007](https://clinicaltrials.gov/study/NCT03569007) stopped for futility in 2022 with 307 of a planned 525 patients. The sponsor said it would analyze whether a responsive subgroup exists; no such analysis has been published, and its absence weakens the case. * **Barrier repair beyond the gut:** Mouse work showing arthritis prevention through barrier restoration ([Tajik et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32332732/)) is the most cited argument for a wider role. Confirmation in humans would strengthen the case substantially; failure would confine larazotide to the gut. * **Metabolic and pancreatic models:** Animal studies in fatty liver disease ([Huang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/40562584/)) and acute pancreatitis ([Karahan et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38441784/)) extend the barrier hypothesis to systemic disease. These are the studies most likely to generate the next human trial. * **The contested target:** Work showing the widely used commercial zonulin assay detects a different blood protein, properdin, rather than the haptoglobin-2 precursor ([Scheffler et al., 2018](https://pubmed.ncbi.nlm.nih.gov/29459849/)) could undercut the drug's entire rationale. Resolving the target's identity is the research question that could most weaken the case. ## Conclusion Larazotide is a small, orally administered protein fragment that acts only inside the gut, where it helps close the seals between the cells lining the intestine. It was built to sit alongside a strict gluten-free diet in celiac disease, never to replace one. The clearest signal is that it blunts digestive symptoms when gluten is deliberately eaten, a finding that repeated across trials and held up when their results were combined. It also sharply limited the rise in the standard celiac blood marker in one trial, and helped children recover faster from a post-viral inflammatory illness in another. Against that, the largest and most rigorous attempt to show relief of lingering symptoms in people already avoiding gluten was abandoned early for lack of effect, and nothing in the record shows the drug protects the intestinal lining itself. Safety looks benign: no serious harm has been traced to the drug, and side effects have tracked placebo closely. The unusual catch is that higher doses work less well, not better. The evidence base carries a clear limitation. Almost all celiac data were generated and funded by the companies that successively owned the compound, and the one comparison treatment — the diet itself — costs health systems nothing, which gives payers a structural reason to prefer it. Much about this compound remains unsettled, including whether the biological target it was designed around exists as described. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**